Markets & Stocks
Stay informed about the latest developments and trends in the cannabis stock market with Business of Cannabis. Discover new investment opportunities, market analysis, and more in our stocks category.
Markets & Stocks · page 13
- Markets & Stocks
European Cannabis Stocks in 2023, MGC’s ArtemiC Approved in Saudi Arabia, & Panaxia Stock Skyrockets
European cannabis stocks in 2023 2023 has been perhaps the hardest financial year to date for the emerging European cannabis sector.
- Markets & Stocks
Celadon Secures £2M in Funding as It Makes Inaugural Product Delivery, Akanda Appoints New CFO, & Curaleaf Launches on TSX
Celadon Pharmaceuticals [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”CEL.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] Celadon Pharmaceuticals this week passed a ‘significant milestone’ as it completed its first ever supply delivery to clients, just days after the successful completion of a £2m fundraise through a placement of new ordinary shares.
- Markets & Stocks
Hellenic Completes Stock Consolidation, MGC Reshuffles Board, & More from Chill Brands
Chill Brands [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”CHLL.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] Chill Brands published a ‘trading update’ to investors this morning, revealing growth in a number of key sales channels, but stopping short of providing any solid revenue figures.
- Markets & Stocks
Jazz Pharma’s Epidiolex Approved in Canada, Apollon Nears Take Over Deal, & Stenocare Expands in Australia
Jazz Pharmaceuticals [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”JAZZ” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] Epidiolex (Epidyolex in the EU and UK), Jazz Pharmaceuticals’ market leading cannabis-based medication, has received authorisation to be prescribed for a number of conditions in Canada.
- Markets & Stocks
Cantourage Reports ‘Singificant Revenue Growth’ for 2023, Europe’s Last Cannabis ETF Closes, & SEED Innovations Publishes Interim Results
Cantourage [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”HIGH.DE” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] Cantourage Group reported its Q3 financial figures this week, celebrating ‘significant revenue growth’ so far in 2023, but slipped back into the red after reporting a positive EBITDA in its interim results in July.
- Markets & Stocks
Celadon Signs New £26m Supply Contract, Hemp & Health Turns To Medical Cannabis, While Cellular Goods & Chill Brands Partner Up
Celadon Pharmaceuticals [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”CEL.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] This morning (November 16), AIM-listed medical cannabis operator Celadon Pharmaceuticals announced that it has signed a new ‘commercial supply agreement’ with an unnamed ‘leading European medical cannabis company’.
- Markets & Stocks
Jazz Pharma Could Be Considering Sale of Cannabis Arm, Ananda Signs New MOU With Nottingham Trent University, & More from Cannovum Cannabis AG
Ananda Developments [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”ANA.AQ” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] Aquis Stock Exchange-listed UK cannabis company Ananda Developments announced a number of key developments across both of its wholly owned subsidiaries this week.
- Markets & Stocks
MGC Pharma & Hellenic Dynamics Both Turn to Share Consolidation as They Secure New Funding, Stenocare Celebrates ‘Milestone’ Launch into Germany
MGC Pharmaceuticals [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”MXC.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] MGC Pharmaceuticals announced this week that it has now secured ‘binding commitments’ for US$7.9m in investment, which the company says will be enough to fund its business plan over the next 12-months.
- Markets & Stocks
Israeli Cannabis Firms Navigate Challenges Amid Hamas Conflict, Cellular Goods Signs New Joint Venture, & More from SEED Innovations
Israeli Cannabis Industry A number of Israel’s leading cannabis companies have issued updates regarding the rapidly evolving situation in the country, which declared war with Hamas last week.
- Markets & Stocks
Northern Leaf ‘Very Confident’ IPO Will Launch This Year, Chill Brands’ Shares Jump On WHSmith Deal
Northern Leaf Jersey-based medical cannabis cultivator Northern Leaf have said they are ‘very confident’ of launching an AIM listing in Q4 this year.
- Markets & Stocks
Yooma Wellness Sells Last ‘Revenue Generating Asset’ Vitality CBD, Hellenic Nears Completion of Facility, & More from Celadon
Yooma Wellness Yooma Wellness this week announced that it had sold its last remaining revenue-generating asset as it warned that should it be unable to ‘secure additional sources of liquidity’, it could be forced into liquidation.
- Markets & Stocks
MGC Pharma In ‘Critical Financial Juncture’ As It Launches Restructuring Plan, Europes First Cannabis ETF To Be Merged As ‘No Longer Viable’, & More From Akanda
MGC Pharmaceuticals [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”MXC.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] MGC Pharmaceuticals, which became the first cannabis company to list on the London Stock Exchange (LSE) in 2021, informed investors this week that due to adverse market conditions it ‘finds itself at a critical financial juncture’.
